Nicotine addiction: insights from recent animal studies
- PMID: 12110988
- DOI: 10.1007/s00213-002-1096-0
Nicotine addiction: insights from recent animal studies
Abstract
Rationale: Recent preclinical behavioral and neurobiological research has characterized important behavioral features and has identified neurobiological substrates that may underlie nicotine reinforcement and addiction.
Objective: To examine recent advances on nicotine exposure in preclinical models, from three perspectives: (a) the chronopharmacokinetics of nicotine, (b) behavioral studies on nicotine reinforcement, withdrawal, and reinstatement/relapse, and (c) effects of nicotine on neurobiological substrates after repeated exposure.
Results: Preclinical studies can be used to operationally model selected aspects of nicotine reinforcement, withdrawal, and reinstatement or relapse. These may be used to investigate the functional in vivo consequences of acute and long-term changes in neuronal acetylcholine receptor populations that follow nicotine exposure. Behavioral studies focusing on distinct stages of nicotine exposure (e.g., active reinforcement vs. cessation or reinstatement) may also be used in parallel with studies on dopaminergic function, a proposed substrate for the reinforcing effects of nicotine, and of opioid receptor function, a possible site of neuroadaptations secondary to nicotine exposure.
Conclusions: While no single current animal model may capture the experience of human smoking or nicotine addiction, increasingly, separate animal models are capturing the full spectrum of behavioral and neurobiological dimensions of this complex condition.
Similar articles
-
Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: a review.Int J Tuberc Lung Dis. 2003 Sep;7(9):811-9. Int J Tuberc Lung Dis. 2003. PMID: 12971663 Review.
-
Measuring impulsivity and modeling its association with cigarette smoking.Behav Cogn Neurosci Rev. 2004 Dec;3(4):261-75. doi: 10.1177/1534582305276838. Behav Cogn Neurosci Rev. 2004. PMID: 15812110 Review.
-
Nicotine's Allure.Neuron. 2009 Sep 10;63(5):564-5. doi: 10.1016/j.neuron.2009.08.029. Neuron. 2009. PMID: 19755099
-
Neurobiology of nicotine addiction: implications for smoking cessation treatment.Am J Med. 2008 Apr;121(4 Suppl 1):S3-10. doi: 10.1016/j.amjmed.2008.01.015. Am J Med. 2008. PMID: 18342164 Review.
-
Neurochemical and behavioral effects of bupropion and mecamylamine in the presence of nicotine.Brain Res. 2006 Oct 30;1117(1):18-24. doi: 10.1016/j.brainres.2006.07.110. Epub 2006 Sep 1. Brain Res. 2006. PMID: 16949560
Cited by
-
Stress, dysregulation of drug reward pathways, and the transition to drug dependence.Am J Psychiatry. 2007 Aug;164(8):1149-59. doi: 10.1176/appi.ajp.2007.05030503. Am J Psychiatry. 2007. PMID: 17671276 Free PMC article. Review.
-
Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release.Biochem Pharmacol. 2010 Aug 1;80(3):402-9. doi: 10.1016/j.bcp.2010.03.018. Epub 2010 Mar 25. Biochem Pharmacol. 2010. PMID: 20346923 Free PMC article.
-
α7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer's Disease.Open Med Chem J. 2010 May 27;4:37-56. doi: 10.2174/1874104501004010037. Open Med Chem J. 2010. PMID: 21249164 Free PMC article.
-
Introduction of unsaturation into the N-n-alkyl chain of the nicotinic receptor antagonists, NONI and NDNI: effect on affinity and selectivity.AAPS J. 2005 Aug 29;7(1):E201-17. doi: 10.1208/aapsj070119. AAPS J. 2005. PMID: 16146341 Free PMC article.
-
Nicotine and nicotinic receptor antagonists potentiate the antidepressant-like effects of imipramine and citalopram.Br J Pharmacol. 2003 Jul;139(6):1196-202. doi: 10.1038/sj.bjp.0705359. Br J Pharmacol. 2003. PMID: 12871839 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources